If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

RXRX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 22.25%

Insider Buying (Last 12 Months): $4,440,853.30

Insider Selling (Last 12 Months): $7,260,607.96

Recursion Pharmaceuticals Insider Trading History Chart

Recursion Pharmaceuticals Share Price & Price History

^$6.98

▼ -0.45 (-6.06%)

As of 03/22/2023 01:00 AM ET

Days: 30 | 90 | 365

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

Recursion Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/8/2023	Christopher Gibson	CEO	Sell	70,890	$8.10	$574,209.00	963,787
3/7/2023	Blake Borgeson	Director	Sell	8,885	$8.33	$74,012.05	7,585,172
3/2/2023	Christopher Gibson	CEO	Sell	18,500	$7.92	$146,520.00	940,927
2/27/2023	Mubadala Investment Co Pjsc	Major Shareholder	Buy	52,500	$7.69	$403,725.00	12,869,423
2/23/2023	Mubadala Investment Co Pjsc	Major Shareholder	Buy	51,864	$7.79	$404,020.56	12,707,805
2/23/2023	Tina Marriott Larson	COO	Sell	8,000	$7.82	$62,560.00	427,844
2/21/2023	Blake Borgeson	Director	Sell	8,885	$7.73	$68,681.05	7,594,057
2/21/2023	Mubadala Investment Co Pjsc	Major Shareholder	Buy	94,418	$7.74	$730,795.32	12,605,000
2/16/2023	Mubadala Investment Co Pjsc	Major Shareholder	Buy	42,682	$7.90	$337,187.80	12,447,200
2/15/2023	Shafique Virani	Insider	Sell	7,486	$8.33	$62,358.38	189,846
2/14/2023	Mubadala Investment Co Pjsc	Major Shareholder	Buy	6,300	$7.95	$50,085.00	12,404,518
2/10/2023	Mubadala Investment Co Pjsc	Major Shareholder	Buy	11,000	$7.98	$87,780.00	12,365,744
2/7/2023	Blake Borgeson	Director	Sell	8,885	$8.81	$78,276.85	7,602,942
1/26/2023	Tina Marriott Larson	COO	Sell	8,000	$8.07	$64,560.00	203,654
1/25/2023	Mubadala Investment Co Pjsc	Major Shareholder	Buy	24,526	$7.88	$193,264.88	12,346,258
1/24/2023	Blake Borgeson	Director	Sell	8,885	$8.71	$77,388.35	7,611,827
1/17/2023	Shafique Virani	Insider	Sell	10,000	$9.16	$91,600.00	73,160
1/10/2023	Blake Borgeson	Director	Sell	8,885	$7.69	$68,325.65	7,620,712
1/9/2023	Mubadala Investment Co Pjsc	Major Shareholder	Buy	76,046	$7.64	$580,991.44	12,252,214
1/5/2023	Christopher Gibson	CEO	Sell	18,500	$7.39	$136,715.00	525,805
1/5/2023	Mubadala Investment Co Pjsc	Major Shareholder	Buy	80,035	$7.38	$590,658.30	12,107,215
1/3/2023	Mubadala Investment Co Pjsc	Major Shareholder	Buy	141,646	$7.50	$1,062,345.00	11,935,288
12/29/2022	Tina Marriott Larson	COO	Sell	8,000	$7.70	$61,600.00	203,654
12/27/2022	Blake Borgeson	Director	Sell	8,885	$7.25	$64,416.25	7,628,272
12/15/2022	Shafique Virani	Insider	Sell	10,000	$8.85	$88,500.00	78,160
12/13/2022	Blake Borgeson	Director	Sell	8,885	$8.96	$79,609.60	7,637,157
12/1/2022	Christopher Gibson	CEO	Sell	37,210	$9.02	$335,634.20	582,805
11/29/2022	Blake Borgeson	Director	Sell	8,885	$8.75	$77,743.75	7,646,042
11/17/2022	Tina Marriott Larson	COO	Sell	16,000	$10.96	$175,360.00	203,654
11/16/2022	Blake Borgeson	Director	Sell	17,770	$11.12	$197,602.40	7,654,927
11/15/2022	Shafique Virani	Insider	Sell	10,000	$12.31	$123,100.00	83,160
11/3/2022	Christopher Gibson	CEO	Sell	36,693	$10.00	$366,930.00	576,016
10/27/2022	Tina Marriott Larson	COO	Sell	16,000	$10.72	$171,520.00	205,107
10/14/2022	Shafique Virani	Insider	Sell	10,000	$10.92	$109,200.00	88,773
10/6/2022	Christopher Gibson	CEO	Sell	36,053	$11.58	$417,493.74	562,959
9/29/2022	Tina Marriott Larson	COO	Sell	16,000	$10.86	$173,760.00	205,107
9/15/2022	Shafique Virani	Insider	Sell	10,000	$13.36	$133,600.00	93,773
8/16/2022	Shafique Virani	Insider	Sell	30,000	$12.61	$378,300.00	98,773
8/16/2022	Tina Marriott Larson	COO	Sell	16,000	$12.60	$201,600.00	295,107
8/4/2022	Christopher Gibson	CEO	Sell	36,825	$9.49	$349,469.25	541,829
7/7/2022	Christopher Gibson	CEO	Sell	37,114	$9.05	$335,881.70	528,904
6/2/2022	Christopher Gibson	CEO	Sell	39,690	$6.09	$241,712.10	516,268
5/4/2022	Christopher Gibson	CEO	Sell	31,830	$6.49	$206,576.70	511,972
4/28/2022	Christopher Gibson	CEO	Sell	37,605	$6.09	$229,014.45	469,608
4/21/2022	Christopher Gibson	CEO	Sell	37,155	$6.31	$234,448.05	420,146
4/18/2022	Christopher Gibson	CEO	Sell	35,836	$6.84	$245,118.24	394,791
4/14/2022	Christopher Gibson	CEO	Sell	34,517	$7.56	$260,948.52	368,117
4/7/2022	Christopher Gibson	CEO	Sell	36,718	$6.54	$240,135.72	314,534
4/5/2022	Christopher Gibson	CEO	Sell	34,472	$7.43	$256,126.96	288,742
3/14/2022	Christopher Gibson	CEO	Sell	230,000	$6.28	$1,444,400.00
3/11/2022	Christopher Gibson	CEO	Sell	100,000	$6.95	$695,000.00
3/7/2022	Christopher Gibson	CEO	Sell	300,000	$7.30	$2,190,000.00
2/22/2022	Christopher Gibson	CEO	Sell	100,000	$10.22	$1,022,000.00
1/31/2022	Christopher Gibson	CEO	Sell	19,858	$11.73	$232,934.34
1/13/2022	Christopher Gibson	CEO	Sell	87,000	$14.33	$1,246,710.00
1/4/2022	Blake Borgeson	Director	Sell	9,625	$18.03	$173,538.75
12/21/2021	Blake Borgeson	Director	Sell	9,625	$18.75	$180,468.75
12/16/2021	Christopher Gibson	CEO	Sell	200	$20.00	$4,000.00
12/16/2021	Tina Marriott Larson	COO	Sell	2,500	$18.74	$46,850.00
12/13/2021	Christopher Gibson	CEO	Sell	100	$20.02	$2,002.00
12/9/2021	Christopher Gibson	CEO	Sell	1,086	$20.01	$21,730.86
12/7/2021	Blake Borgeson	Director	Sell	9,625	$20.32	$195,580.00
12/7/2021	Christopher Gibson	CEO	Sell	3,125	$20.51	$64,093.75
11/19/2021	Dean Y. Li	Director	Sell	13,474	$20.20	$272,174.80
11/18/2021	Tina Marriott Larson	COO	Sell	2,500	$18.92	$47,300.00
11/17/2021	Dean Y. Li	Director	Sell	5,626	$20.04	$112,745.04

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

SEC Filings (Institutional Ownership Changes) for Recursion Pharmaceuticals (NASDAQ:RXRX)

63.62% of Recursion Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Recursion Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/22/2023	Teachers Retirement System of The State of Kentucky	174,435	$1.35M	0.0%	+6.1%	0.092%
2/16/2023	Alliancebernstein L.P.	390,605	$3.01M	0.0%	-87.9%	0.206%
2/15/2023	Jane Street Group LLC	27,093	$0.21M	0.0%	-47.6%	0.014%
2/15/2023	Lazard Asset Management LLC	163,909	$1.26M	0.0%	-46.1%	0.086%
2/15/2023	State of Wisconsin Investment Board	46,181	$0.36M	0.0%	-36.3%	0.024%
2/15/2023	Schonfeld Strategic Advisors LLC	81,204	$0.63M	0.0%	-30.6%	0.043%
2/15/2023	Squarepoint Ops LLC	69,800	$0.54M	0.0%	N/A	0.037%
2/15/2023	Laurion Capital Management LP	4,825,735	$37.21M	0.2%	+5.2%	2.546%
2/15/2023	Legal & General Group Plc	93,970	$0.73M	0.0%	+5.0%	0.050%
2/15/2023	Millennium Management LLC	695,373	$5.36M	0.0%	+190.5%	0.367%
2/15/2023	Morgan Stanley	333,171	$2.57M	0.0%	+20.7%	0.176%
2/15/2023	Norges Bank	4,371,313	$33.70M	0.0%	N/A	2.306%
2/15/2023	E Fund Management Co. Ltd.	27,111	$0.21M	0.0%	+128.6%	0.014%
2/15/2023	Alps Advisors Inc.	123,165	$0.95M	0.0%	+36.6%	0.065%
2/14/2023	Vident Investment Advisory LLC	13,581	$0.11M	0.0%	+16.6%	0.007%
2/14/2023	Price T Rowe Associates Inc. MD	75,919	$0.59M	0.0%	+109.7%	0.040%
2/14/2023	Amundi	7,189	$57K	0.0%	+69.6%	0.004%
2/14/2023	Alpine Global Management LLC	15,533	$0.12M	0.0%	N/A	0.008%
2/14/2023	Two Sigma Investments LP	73,103	$0.56M	0.0%	N/A	0.039%
2/13/2023	Platinum Investment Management Ltd.	2,710,339	$20.90M	0.8%	+20.4%	1.430%
2/13/2023	Charles Schwab Investment Management Inc.	984,681	$7.59M	0.0%	+8.9%	0.519%
2/13/2023	Deutsche Bank AG	70,973	$0.55M	0.0%	+22.2%	0.037%
2/13/2023	Nikko Asset Management Americas Inc.	454,522	$3.50M	0.1%	-7.4%	0.240%
2/13/2023	Barclays PLC	296,600	$2.29M	0.0%	+164.3%	0.156%
2/13/2023	Renaissance Technologies LLC	193,900	$1.50M	0.0%	+1,175.7%	0.102%
2/13/2023	The Manufacturers Life Insurance Company	55,778	$0.43M	0.0%	+2.7%	0.029%
2/13/2023	Credit Suisse AG	1,575,590	$12.15M	0.0%	+0.7%	0.831%
2/13/2023	Geode Capital Management LLC	2,609,948	$20.12M	0.0%	+11.9%	1.377%
2/13/2023	GSA Capital Partners LLP	22,603	$0.17M	0.0%	N/A	0.012%
2/13/2023	JPMorgan Chase & Co.	173,336	$1.34M	0.0%	-4.3%	0.091%
2/13/2023	Artal Group S.A.	960,204	$7.40M	0.4%	+113.4%	0.507%
2/10/2023	Bank of America Corp DE	421,864	$3.25M	0.0%	+112.1%	0.223%
2/10/2023	Schroder Investment Management Group	159,964	$1.23M	0.0%	+47.0%	0.084%
2/10/2023	Connor Clark & Lunn Investment Management Ltd.	144,013	$1.11M	0.0%	N/A	0.076%
2/10/2023	Aigen Investment Management LP	20,250	$0.16M	0.0%	N/A	0.011%
2/9/2023	Hamilton Lane Advisors LLC	96,474	$0.74M	0.3%	+72.7%	0.051%
2/9/2023	First Trust Advisors LP	241,147	$1.86M	0.0%	+86.3%	0.127%
2/9/2023	Dimensional Fund Advisors LP	189,928	$1.46M	0.0%	N/A	0.100%
2/9/2023	Principal Financial Group Inc.	34,483	$0.27M	0.0%	+4.9%	0.018%
2/9/2023	Citigroup Inc.	232,827	$1.80M	0.0%	+44.1%	0.123%
2/8/2023	UBS Group AG	361,895	$2.79M	0.0%	+1,859.9%	0.191%
2/8/2023	Swiss National Bank	119,600	$0.92M	0.0%	+2.7%	0.063%
2/8/2023	Russell Investments Group Ltd.	131,956	$1.02M	0.0%	-2.3%	0.070%
2/8/2023	Dakota Wealth Management	13,438	$0.10M	0.0%	-50.0%	0.007%
2/7/2023	LPL Financial LLC	45,860	$0.35M	0.0%	+9.8%	0.024%
2/7/2023	Handelsbanken Fonder AB	18,800	$0.15M	0.0%	+41.4%	0.010%
2/7/2023	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	18,733	$0.14M	0.0%	N/A	0.010%
2/6/2023	Daiwa Securities Group Inc.	6,903	$53K	0.0%	+1,029.8%	0.004%
2/6/2023	Jackson Creek Investment Advisors LLC	77,011	$0.59M	0.3%	N/A	0.041%
2/2/2023	SG Americas Securities LLC	28,022	$0.22M	0.0%	+54.5%	0.015%
2/2/2023	ProShare Advisors LLC	32,611	$0.25M	0.0%	+12.8%	0.017%
2/1/2023	Zurcher Kantonalbank Zurich Cantonalbank	18,954	$0.15M	0.0%	+26.7%	0.010%
2/1/2023	Kinnevik AB publ	7,653,061	$59.01M	33.3%	N/A	4.037%
2/1/2023	Cypress Point Wealth Management LLC	14,219	$0.11M	0.2%	+40.0%	0.008%
1/30/2023	Sumitomo Mitsui Trust Holdings Inc.	454,522	$3.50M	0.0%	-7.4%	0.240%
1/24/2023	ARK Investment Management LLC	3,099,490	$23.90M	0.2%	-7.7%	1.635%
1/24/2023	Baillie Gifford & Co.	24,820,850	$191.37M	0.2%	+14.9%	12.980%
1/11/2023	Foundations Investment Advisors LLC	16,656	$0.13M	0.0%	-23.3%	0.009%
12/8/2022	Bank of New York Mellon Corp	503,941	$5.36M	0.0%	+26.2%	0.266%
11/22/2022	Teachers Retirement System of The State of Kentucky	164,435	$1.75M	0.0%	N/A	0.087%
11/21/2022	California State Teachers Retirement System	96,266	$1.02M	0.0%	-2.3%	0.051%
11/16/2022	Advisory Research Inc.	96,803	$1.03M	0.1%	+56.6%	0.056%
11/16/2022	BNP Paribas Arbitrage SNC	107,034	$1.14M	0.0%	N/A	0.062%
11/15/2022	Alliancebernstein L.P.	3,237,344	$34.45M	0.0%	-10.1%	1.870%
11/15/2022	State Street Corp	4,555,759	$48.47M	0.0%	+114.3%	2.632%
11/15/2022	Trexquant Investment LP	11,800	$0.13M	0.0%	-78.3%	0.007%
11/15/2022	Two Sigma Ventures LP	903,400	$9.61M	100.0%	-50.0%	0.522%
11/15/2022	UBS Asset Management Americas Inc.	76,879	$0.82M	0.0%	+49.4%	0.044%
11/15/2022	Vanguard Group Inc.	8,380,986	$89.17M	0.0%	+19.9%	4.842%
11/15/2022	Platinum Investment Management Ltd.	2,251,971	$23.96M	1.0%	-11.2%	1.301%
11/15/2022	Price T Rowe Associates Inc. MD	36,206	$0.39M	0.0%	+58.8%	0.021%
11/15/2022	Quantamental Technologies LLC	11,981	$0.13M	0.0%	N/A	0.007%
11/15/2022	Martingale Asset Management L P	25,200	$0.27M	0.0%	+127.0%	0.015%
11/15/2022	First Trust Advisors LP	129,438	$1.38M	0.0%	N/A	0.075%
11/15/2022	Bank of New York Mellon Corp	503,941	$5.36M	0.0%	+26.2%	0.291%
11/15/2022	BlackRock Inc.	9,767,040	$103.92M	0.0%	+18.5%	5.643%
11/14/2022	Cubist Systematic Strategies LLC	111,575	$1.19M	0.0%	+376.7%	0.064%
11/14/2022	Bienville Capital Management LLC	60,938	$0.65M	0.3%	+66.7%	0.035%
11/14/2022	Renaissance Technologies LLC	15,200	$0.16M	0.0%	-94.2%	0.009%
11/14/2022	Lazard Asset Management LLC	304,212	$3.24M	0.0%	+5.0%	0.176%
11/14/2022	Nuveen Asset Management LLC	847,137	$9.01M	0.0%	+49.0%	0.489%
11/14/2022	Crown Advisors Management Inc.	30,000	$0.32M	0.3%	N/A	0.017%
11/14/2022	Hsbc Holdings PLC	10,201	$0.11M	0.0%	-22.0%	0.006%
11/14/2022	E Fund Management Co. Ltd.	11,859	$0.13M	0.0%	N/A	0.007%
11/10/2022	Dakota Wealth Management	26,901	$0.29M	0.0%	N/A	0.016%
11/10/2022	ExodusPoint Capital Management LP	45,832	$0.49M	0.0%	-76.1%	0.026%
11/10/2022	Tower Research Capital LLC TRC	15,411	$0.16M	0.0%	+223.6%	0.009%
11/10/2022	UBS Group AG	18,465	$0.20M	0.0%	+270.3%	0.011%
11/10/2022	Mitsubishi UFJ Trust & Banking Corp	367,390	$3.91M	0.0%	-1.6%	0.212%
11/9/2022	Massachusetts Financial Services Co. MA	950,594	$10.11M	0.0%	-28.4%	0.549%
11/8/2022	Hamilton Lane Advisors LLC	55,850	$0.59M	0.2%	+266.8%	0.032%
11/8/2022	Manchester Capital Management LLC	26,880	$0.29M	0.0%	+100.0%	0.016%
11/7/2022	Nisa Investment Advisors LLC	50,384	$0.54M	0.0%	-34.9%	0.029%
11/4/2022	Russell Investments Group Ltd.	135,073	$1.44M	0.0%	+5.1%	0.079%
11/4/2022	Ieq Capital LLC	17,920	$0.19M	0.0%	N/A	0.010%
11/3/2022	Teacher Retirement System of Texas	16,043	$0.17M	0.0%	N/A	0.009%
11/3/2022	The Manufacturers Life Insurance Company	54,320	$0.58M	0.0%	-1.9%	0.032%
11/3/2022	Barclays PLC	112,234	$1.20M	0.0%	+448.2%	0.066%
11/2/2022	Rockefeller Capital Management L.P.	7,319	$77K	0.0%	+23.2%	0.004%
11/2/2022	DekaBank Deutsche Girozentrale	60,000	$0.65M	0.0%	+55.8%	0.035%

Data available starting January 2016

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $6.98

$6.95

$7.47

50 Day Range

MA: $8.17

$6.98

$9.64

52 Week Range

Now: $6.98

$4.92

$14.18

Volume

862,731 shs

Average Volume

961,801 shs

Market Capitalization

$1.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Recursion Pharmaceuticals?: Recursion Pharmaceuticals' top insider investors include:
Mubadala Investment Co Pjsc (Major Shareholder)
Blake Borgeson (Director)
Christopher Gibson (CEO)
Tina Marriott Larson (COO)
Shafique Virani (Insider)
Dean Y Li (Director)
Learn More about top insider investors at Recursion Pharmaceuticals.
Who are the major institutional investors of Recursion Pharmaceuticals?: Recursion Pharmaceuticals' top institutional investors include:
Baillie Gifford & Co. — 12.98%
Kinnevik AB publ — 4.04%
Laurion Capital Management LP — 2.55%
Norges Bank — 2.31%
ARK Investment Management LLC — 1.64%
Platinum Investment Management Ltd. — 1.43%
Learn More about top institutional investors of Recursion Pharmaceuticals stock.
Which institutional investors are selling Recursion Pharmaceuticals stock?: Within the previous quarter, RXRX stock was sold by these institutional investors:
Alliancebernstein L.P.
ARK Investment Management LLC
Lazard Asset Management LLC
Sumitomo Mitsui Trust Holdings Inc.
Nikko Asset Management Americas Inc.
Schonfeld Strategic Advisors LLC
State of Wisconsin Investment Board
Jane Street Group LLC
During the last year, company insiders that have sold Recursion Pharmaceuticals company stock include:
Mubadala Investment Co Pjsc (Major Shareholder)
Blake Borgeson (Director)
Christopher Gibson (CEO)
Tina Marriott Larson (COO)
Learn More investors selling Recursion Pharmaceuticals stock.
Which institutional investors are buying Recursion Pharmaceuticals stock?: In the previous quarter, RXRX stock was purchased by institutional investors including:
Kinnevik AB publ
Norges Bank
Baillie Gifford & Co.
Artal Group S.A.
Platinum Investment Management Ltd.
Millennium Management LLC
UBS Group AG
Geode Capital Management LLC

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

RXRX Insider Trading

Recursion Pharmaceuticals Insider Trading History Chart

Recursion Pharmaceuticals Share Price & Price History

Recursion Pharmaceuticals Insider Trading History

SEC Filings (Institutional Ownership Changes) for Recursion Pharmaceuticals (NASDAQ:RXRX)

Institutional Buying and Selling by Quarter

Recursion Pharmaceuticals Institutional Trading History

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Who are the company insiders with the largest holdings of Recursion Pharmaceuticals?

Who are the major institutional investors of Recursion Pharmaceuticals?

Which institutional investors are selling Recursion Pharmaceuticals stock?

Which institutional investors are buying Recursion Pharmaceuticals stock?